<p>Syndax Pharmaceuticals, Inc.（纳斯达克代码：SNDX - 获取免费报告）的股票在周二交易中下跌了 7.4%，原因是其财报令人失望。该股最低交易价格为 14.23 美元，最后交易价格为 14.34 美元。在午盘交易中，共交易了 1,069,083 股，较平均每日交易量 2,257,449 股下降了 53%。该股此前收盘价为 15.48 美元。</p>
<p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
<p>该公司报告的每股收益为（$1.10），低于市场共识预期的（$0.31），差距为（$0.79）。该公司本季度的收入为 768 万美元，而分析师预期为 8632 万美元。</p>
<h2>华尔街分析师预测增长</h2>
<p>多家券商最近对 SNDX 发表了看法。StockNews.com 在 11 月 23 日的报告中将 Syndax Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。花旗集团在 11 月 19 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 37.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。加拿大丰业银行在 1 月 8 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 18.00 美元下调至 16.00 美元，并对该股给予 “行业表现” 评级。摩根大通在 11 月 21 日的报告中将 Syndax Pharmaceuticals 的目标价从 33.00 美元上调至 38.00 美元，并给予该股 “增持” 评级。最后，高盛在 11 月 7 日的报告中将 Syndax Pharmaceuticals 的目标价从 30.00 美元上调至 33.00 美元，并给予该公司 “买入” 评级。一位分析师对该股给予了 “卖出” 评级，一位给予了 “持有” 评级，九位给予了 “买入” 评级。根据 MarketBeat 的数据，Syndax Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 36.20 美元。</p>
<p><strong>获取我们关于 SNDX 的最新研究报告</strong></p>
<h2>内部人士下注</h2>
<p>在其他新闻中，首席执行官 Michael A. Metzger 在 2 月 10 日的交易中出售了 13,288 股该股票。该股以平均价格 15.50 美元出售，总价值为 205,964.00 美元。出售后，首席执行官现在直接持有 300,121 股公司股票，价值约为 4,651,875.50 美元。这代表着他们持股比例下降了 4.24%。该交易已在向 SEC 提交的法律文件中披露，您可以通过此链接访问。此外，内部人士 Neil Gallagher 在 2 月 10 日的交易中出售了 4,618 股公司的股票。该股以平均价格 15.50 美元出售，总交易额为 71,579.00 美元。交易完成后，该内部人士现在持有 85,095 股公司股票，价值约为 1,318,972.50 美元。该交易使其持股比例下降了 5.15%。该出售的披露信息可以在这里找到。在上个季度，内部人士共出售了 21,683 股公司股票，价值 336,087 美元。公司内部人士持有公司股票的 4.10%。</p>
<h2>机构资金流入和流出</h2>
<p>多家对冲基金和其他机构投资者最近调整了对该公司的持股。道富集团在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 4.1%。道富集团目前持有 3,770,826 股公司股票，价值 72,588,000 美元，在此期间又增持了 148,491 股。Soleus Capital Management L.P.在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P.目前持有 2,492,000 股公司股票，价值 32,944,000 美元，在此期间又购买了 1,401,016 股。Assenagon Asset Management S.A.在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 343.0%。Assenagon Asset Management S.A.目前持有 2,064,456 股公司股票，价值 27,292,000 美元，在上个季度又购买了 1,598,428 股。Geode Capital Management LLC 在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 3.5%。Geode Capital Management LLC 目前持有 1,977,082 股公司股票，价值 38,066,000 美元，在此期间又购买了 66,459 股。最后，富兰克林资源公司在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 13.4%。富兰克林资源公司目前持有 1,763,277 股公司股票，价值 34,948,000 美元，在上个季度又购买了 208,043 股。</p>
<h2>Syndax Pharmaceuticals 股票表现</h2>
<p>该公司的市值为 12.3 亿美元，市盈率为-3.97，贝塔系数为 0.90。该公司的 50 日移动平均线为 14.23 美元，200 日移动平均线为 16.75 美元。</p>
<h2>关于 Syndax Pharmaceuticals</h2>
<p>（获取免费报告）</p>
<p>Syndax Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的、针对 menin-MLL 结合相互作用的小分子抑制剂，用于治疗 KMT2A 重排的急性白血病和实体肿瘤；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
<h2>特色故事</h2>
<ul>
<li>五只我们更看好的股票超过 Syndax Pharmaceuticals</li>
<li>投资者需要了解的击败市场的信息</li>
<li>特斯拉股票：寻找底部可能需要时间</li>
<li>投资石油股票的方式和原因</li>
<li>Duolingo：这只被打压的股票即将反弹 38%</li>
<li>股息贵族的最佳名单：通过贵族指数积累财富</li>
<li>Zoom 股票：在 Skype 退出后引领视频市场</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
<p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Syndax Pharmaceuticals 并不在名单上。</p>
<p>虽然 Syndax Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Syndax制药

<p>Syndax Pharmaceuticals（纳斯达克代码：SNDX）股价下跌 7.4%，至 14.34 美元，因财报令人失望，每股收益（EPS）低于预期 0.79 美元，报告收入为 768 万美元，远低于 8632 万美元的预期。分析师的评级不一，其中一位为卖出，另一位为持有，九位为买入。首席执行官 Michael A. Metzger 和内部人士 Neil Gallagher 最近出售了股份，减少了他们的持股比例。机构投资者增加了持股，其中 State Street Corp 和 Soleus Capital Management 是 notable investors。该公司的市值为 12.3 亿美元，专注于癌症治疗</p>

<p>Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX - Get Free Report) dropped 7.4% during trading on Tuesday following a dissappointing earnings announcement. The stock traded as low as $14.23 and last traded at $14.34. 1,069,083 shares were traded during mid-day trading, a decline of 53% from the average daily volume of 2,257,449 shares. The stock had previously closed at $15.48.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc.（纳斯达克代码：SNDX - 获取免费报告）的股票在周二交易中下跌了 7.4%，原因是其财报令人失望。该股最低交易价格为 14.23 美元，最后交易价格为 14.34 美元。在午盘交易中，共交易了 1,069,083 股，较平均每日交易量 2,257,449 股下降了 53%。该股此前收盘价为 15.48 美元。</p>
</div><p>Get <strong>Syndax Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Syndax Pharmaceuticals</strong> 的提醒：</p>
</div><p>The company reported ($1.10) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.79). The firm had revenue of $7.68 million for the quarter, compared to analysts' expectations of $86.32 million.</p>
<div class="lb-trans"><p>该公司报告的每股收益为（$1.10），低于市场共识预期的（$0.31），差距为（$0.79）。该公司本季度的收入为 768 万美元，而分析师预期为 8632 万美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>A number of brokerages have recently weighed in on SNDX. StockNews.com lowered shares of Syndax Pharmaceuticals from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday, November 23rd. Citigroup boosted their target price on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a &#34;buy&#34; rating in a research note on Tuesday, November 19th. Scotiabank reduced their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a &#34;sector perform&#34; rating on the stock in a research report on Wednesday, January 8th. JPMorgan Chase &amp; Co. raised their target price on shares of Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an &#34;overweight&#34; rating in a report on Thursday, November 21st. Finally, The Goldman Sachs Group upped their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 7th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $36.20.</p>
<div class="lb-trans"><p>多家券商最近对 SNDX 发表了看法。StockNews.com 在 11 月 23 日的报告中将 Syndax Pharmaceuticals 的股票评级从 “持有” 下调至 “卖出”。花旗集团在 11 月 19 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 37.00 美元上调至 45.00 美元，并给予该公司 “买入” 评级。加拿大丰业银行在 1 月 8 日的研究报告中将 Syndax Pharmaceuticals 的目标价从 18.00 美元下调至 16.00 美元，并对该股给予 “行业表现” 评级。摩根大通在 11 月 21 日的报告中将 Syndax Pharmaceuticals 的目标价从 33.00 美元上调至 38.00 美元，并给予该股 “增持” 评级。最后，高盛在 11 月 7 日的报告中将 Syndax Pharmaceuticals 的目标价从 30.00 美元上调至 33.00 美元，并给予该公司 “买入” 评级。一位分析师对该股给予了 “卖出” 评级，一位给予了 “持有” 评级，九位给予了 “买入” 评级。根据 MarketBeat 的数据，Syndax Pharmaceuticals 目前的共识评级为 “适度买入”，共识目标价为 36.20 美元。</p>
</div><p><strong>Get Our Latest Research Report on SNDX</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 SNDX 的最新研究报告</strong></p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other news, CEO Michael A. Metzger sold 13,288 shares of the stock in a transaction on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares of the company's stock, valued at approximately $4,651,875.50. This represents a 4.24 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Neil Gallagher sold 4,618 shares of the company's stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total transaction of $71,579.00. Following the completion of the transaction, the insider now owns 85,095 shares in the company, valued at approximately $1,318,972.50. The trade was a 5.15 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 21,683 shares of company stock worth $336,087. Company insiders own 4.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他新闻中，首席执行官 Michael A. Metzger 在 2 月 10 日的交易中出售了 13,288 股该股票。该股以平均价格 15.50 美元出售，总价值为 205,964.00 美元。出售后，首席执行官现在直接持有 300,121 股公司股票，价值约为 4,651,875.50 美元。这代表着他们持股比例下降了 4.24%。该交易已在向 SEC 提交的法律文件中披露，您可以通过此链接访问。此外，内部人士 Neil Gallagher 在 2 月 10 日的交易中出售了 4,618 股公司的股票。该股以平均价格 15.50 美元出售，总交易额为 71,579.00 美元。交易完成后，该内部人士现在持有 85,095 股公司股票，价值约为 1,318,972.50 美元。该交易使其持股比例下降了 5.15%。该出售的披露信息可以在这里找到。在上个季度，内部人士共出售了 21,683 股公司股票，价值 336,087 美元。公司内部人士持有公司股票的 4.10%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>A number of hedge funds and other institutional investors have recently modified their holdings of the business. State Street Corp raised its position in Syndax Pharmaceuticals by 4.1% in the third quarter. State Street Corp now owns 3,770,826 shares of the company's stock worth $72,588,000 after acquiring an additional 148,491 shares during the period. Soleus Capital Management L.P. grew its holdings in Syndax Pharmaceuticals by 128.4% during the fourth quarter. Soleus Capital Management L.P. now owns 2,492,000 shares of the company's stock valued at $32,944,000 after purchasing an additional 1,401,016 shares during the period. Assenagon Asset Management S.A. increased its position in Syndax Pharmaceuticals by 343.0% in the fourth quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company's stock worth $27,292,000 after buying an additional 1,598,428 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Syndax Pharmaceuticals by 3.5% in the third quarter. Geode Capital Management LLC now owns 1,977,082 shares of the company's stock worth $38,066,000 after buying an additional 66,459 shares during the period. Finally, Franklin Resources Inc. lifted its position in shares of Syndax Pharmaceuticals by 13.4% during the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company's stock valued at $34,948,000 after buying an additional 208,043 shares in the last quarter.</p>
<div class="lb-trans"><p>多家对冲基金和其他机构投资者最近调整了对该公司的持股。道富集团在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 4.1%。道富集团目前持有 3,770,826 股公司股票，价值 72,588,000 美元，在此期间又增持了 148,491 股。Soleus Capital Management L.P.在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 128.4%。Soleus Capital Management L.P.目前持有 2,492,000 股公司股票，价值 32,944,000 美元，在此期间又购买了 1,401,016 股。Assenagon Asset Management S.A.在第四季度将其在 Syndax Pharmaceuticals 的持股增加了 343.0%。Assenagon Asset Management S.A.目前持有 2,064,456 股公司股票，价值 27,292,000 美元，在上个季度又购买了 1,598,428 股。Geode Capital Management LLC 在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 3.5%。Geode Capital Management LLC 目前持有 1,977,082 股公司股票，价值 38,066,000 美元，在此期间又购买了 66,459 股。最后，富兰克林资源公司在第三季度将其在 Syndax Pharmaceuticals 的持股增加了 13.4%。富兰克林资源公司目前持有 1,763,277 股公司股票，价值 34,948,000 美元，在上个季度又购买了 208,043 股。</p>
</div><h2>Syndax Pharmaceuticals Stock Performance</h2>
<div class="lb-trans"><h2>Syndax Pharmaceuticals 股票表现</h2>
</div><p>The company has a market capitalization of $1.23 billion, a PE ratio of -3.97 and a beta of 0.90. The company's fifty day moving average is $14.23 and its 200-day moving average is $16.75.</p>
<div class="lb-trans"><p>该公司的市值为 12.3 亿美元，市盈率为-3.97，贝塔系数为 0.90。该公司的 50 日移动平均线为 14.23 美元，200 日移动平均线为 16.75 美元。</p>
</div><h2>About Syndax Pharmaceuticals</h2>
<div class="lb-trans"><h2>关于 Syndax Pharmaceuticals</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，开发用于癌症治疗的疗法。其主要产品候选药物包括 revumenib，一种强效、选择性的、针对 menin-MLL 结合相互作用的小分子抑制剂，用于治疗 KMT2A 重排的急性白血病和实体肿瘤；以及 SNDX-6352 或 axatilimab，一种单克隆抗体，阻断集落刺激因子 1（CSF-1）受体，用于治疗慢性移植物抗宿主病（cGVHD）和特发性肺纤维化（IPF）患者。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Syndax Pharmaceuticals</li>
<li>What Investors Need to Know to Beat the Market</li>
<li>Tesla Stock: Finding a Bottom May Take Time</li>
<li>The How And Why of Investing in Oil Stocks</li>
<li>Duolingo: This Beaten-Down Stock Is About to Rally 38%</li>
<li>Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index</li>
<li>Zoom Stock: Leading the Video Market After Skype’s Exit</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过 Syndax Pharmaceuticals</li>
<li>投资者需要了解的击败市场的信息</li>
<li>特斯拉股票：寻找底部可能需要时间</li>
<li>投资石油股票的方式和原因</li>
<li>Duolingo：这只被打压的股票即将反弹 38%</li>
<li>股息贵族的最佳名单：通过贵族指数积累财富</li>
<li>Zoom 股票：在 Skype 退出后引领视频市场</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Syndax Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Syndax Pharmaceuticals 吗？</h2>
</div><p>Before you consider Syndax Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Syndax Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syndax Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Syndax Pharmaceuticals 并不在名单上。</p>
</div><p>While Syndax Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Syndax Pharmaceuticals 目前在分析师中有中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Syndax 制药（NASDAQ:SNDX）股价因令人失望的收益下跌 7.4%